Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Mar 6, 2024
- Accession no.
- 0001447362-24-000021
- Filed
- Mar 6, 2024
- Trade date
- Mar 4-5, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $88.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 5, 2024 | Common Stock | MOption exerciseAcquired | +10,686 | $3.72 | +$39,751.92 | 78,604 | Direct | |
| Mar 5, 2024 | Common Stock | SSaleDisposed | −4,131 | $21.41 | −$88,444.71 | 74,473 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 4, 2024 | Common Stock | AGrant or awardAcquired | +124,437 | $0.00 | $0 | 124,437 | Direct | |
| Mar 5, 2024 | Common Stock | MOption exerciseDisposed | −10,686 | $3.72 | −$39,751.92 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.